The company is “reiterating 2026 total revenue guidance of 10% to 13% growth, or $570 million to $582 million, driven by testing revenue guidance of 14% to 16% growth, or $560 million to $570 million, excluding the contribution from new tests. Further, adjusted EBITDA margin is expected to be approximately 25%.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- VCYT Earnings this Week: How Will it Perform?
- Cathie Wood Buys the Dip in Joby Aviation (JOBY), Sells Teradyne (TER) Near Highs
- Cathie Wood Invests Over $3M Into Crypto Stock, Trims Stakes in Kratos Defense and TWST
- Veracyte: Strong Fundamentals and Margin Profile Offset by Execution Risks and Limited Valuation Upside, Justifying Hold Rating
- Veracyte: Strong Near-Term Performance but Execution and Valuation Risks Justify Sell Rating